Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

被引：1

作者：

Tembhare, Prashant Ramesh ^{[1
,2
]}

Sriram, Harshini ^{[1
,2
]}

Khanka, Twinkle ^{[2
]}

Gawai, Sanghamitra ^{[2
]}

Ghogale, Sitaram ^{[2
]}

Deshpande, Nilesh ^{[2
]}

Bagal, Bhausaheb ^{[1
,3
,4
]}

Chatterjee, Gaurav ^{[5
]}

Hasan, Syed Khizer ^{[6
]}

Rajpal, Sweta ^{[1
,2
]}

Patkar, Nikhil ^{[1
,7
]}

Jain, Hasmukh ^{[3
,8
]}

Shetty, Dhanlaxmi Lalit ^{[9
]}

Ghosh, Kinjalka ^{[10
]}

Inamdar, Nitin ^{[11
]}

Punatar, Sachin ^{[1
,3
]}

Gokarn, Anant ^{[1
,12
]}

Sengar, Manju ^{[13
,14
]}

Khattry, Navin ^{[15
]}

Subramanian, Papagudi Ganesan ^{[1
,5
]}

Gujral, Sumeet ^{[1
,16
]}

机构：

[1] Homi Bhabha Natl Inst, Mumbai, Maharashtra, India

[2] Tata Mem Hosp, Hematopathol Lab, ACTREC, Navi Mumbai, India

[3] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India

[4] Tata Mem Hosp, Dept Med Oncol, Adult Hematolymphoid Dis Management Grp, Mumbai, Maharashtra, India

[5] Tata Mem Hosp, Hematopathol Lab, Navi Mumbai, ACTREC, Navi Mumbai, India

[6] Tata Mem Hosp, Navi Mumbai, ACTREC, Navi Mumbai, India

[7] Tata Mem Hosp, Tata Mem Ctr, Affiliated Homi Bhabha Natl Inst, Haematopathol Lab, Navi Mumbai, India

[8] Tata Mem Hosp, Adult Hematolymphoid Dis Management Grp, Mumbai, Maharashtra, India

[9] Tata Mem Hosp, Dept Med Oncol, ACTREC, Adult Hematolymphoid Dis Management Grp, Navi Mumbai, India

[10] Homi Bhabha Natl Inst, Tata Mem Ctr, Dept Biochem, Mumbai, Maharashtra, India

[11] Tata Mem Hosp, Dept Biochem, Mumbai, Maharashtra, India

[12] Tata Mem Hosp, Dept Med Oncol, BMT Unit, Adv Ctr Treatment Res & Educ Canc ACTREC, Mumbai, Maharashtra, India

[13] Homibhaba Natl Inst, Mumbai, Maharashtra, India

[14] Tata Mem Hosp, Dept Med Oncol, Hematolymphoid Dis Management Grp, Mumbai, Maharashtra, India

[15] Tata Mem Hosp, Dept Bone Marrow Transplant, ACTREC, Navi Mumbai, India

[16] Tata Mem Hosp, Hematopathol Lab, Mumbai, Maharashtra, India

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165715

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1135 / 1136

页数：2

共 7 条

[1] Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
Tembhare, Prashant R.
Sriram, Harshini
Khanka, Twinkle
Gawai, Sanghamitra
Bagal, Bhausaheb
Ghogale, Sitaram G.
Deshpande, Nilesh
Girase, Karishma
Patil, Jagruti
Hasan, Syed Khaizer
Shetty, Dhanalaxmi
Ghosh, Kinjalka
Chatterjee, Gaurav
Rajpal, Sweta
Patkar, Nikhil V.
Jain, Hasmukh
Punatar, Sachin
Gokarn, Anant
Nayak, Lingaraj
Mirgh, Sumeet
Jindal, Nishant
Sengar, Manju
Khattry, Navin
Subramanian, Papagudi G.
Gujral, Sumeet
HEMASPHERE, 2024, 8 (04):
[2] Mobilization of autologous peripheral blood haematopoietic stem cells for newly-diagnosed multiple myeloma treated with cyclophosphamide, thalidomide and dexamethasone regimen, experience in Macedonia
Georgievski, B.
Cevreska, L.
Stojanoski, Z.
Stavrik, S. Genadieva
Chadievski, L.
Grubovic, R.
Useini, S.
Veljanovska, A. Pivkova
BONE MARROW TRANSPLANTATION, 2013, 48 : S545 - S545
[3] Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study
Derman, Benjamin A.
Kansagra, Ankit
Zonder, Jeffrey
Stefka, Andrew T.
Grinblatt, David L.
Anderson, Larry D., Jr.
Gurbuxani, Sandeep
Narula, Sunil
Rayani, Shayan
Major, Ajay
Kin, Andrew
Jiang, Ken
Karrison, Theodore
Jasielec, Jagoda
Jakubowiak, Andrzej J.
JAMA ONCOLOGY, 2022, 8 (09) : 1278 - 1286
[4] High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Bertamini, Luca
Oliva, Stefania
Rota-Scalabrini, Delia
Paris, Laura
More, Sonia
Corradini, Paolo
Ledda, Antonio
Gentile, Massimo
De Sabbata, Giovanni
Pietrantuono, Giuseppe
Pascarella, Anna
Tosi, Patrizia
Curci, Paola
Gilestro, Milena
Capra, Andrea
Galieni, Piero
Pisani, Francesco
Annibali, Ombretta
Monaco, Federico
Liberati, Anna Marina
Palmieri, Salvatore
Luppi, Mario
Zambello, Renato
Fazio, Francesca
Belotti, Angelo
Tacchetti, Paola
Musto, Pellegrino
Boccadoro, Mario
Gay, Francesca
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) : 3120 - +
[5] Prognostic Relevance of the Proportion of Residual Polyclonal Plasma Cells in the Diagnostic Bone Marrow of Newly Diagnosed Multiple Myeloma Patients Managed Without Autologous Stem Cell Transplantation
Tembhare, Prashant
Gudapati, Prathyusha
Ghogale, Sitaram
Inamdar, Nitin
Khanka, Twinkle
Deshpande, Nilesh
Yajamanam, Badrinath
Chatterjee, Gaurav
Gawai, Sangamitra
Amare, Prathibha
Bagal, Bhausaheb
Jain, Hasmukh
Patkar, Nikhil
Sengar, Manju
Khattry, Navin
Subramanian, P. G.
Gujral, Sumeet
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E238 - E239
[6] Prognostic Relevance of Clonal Circulating Plasma Cells Detected By Multiparameter Flow Cytometry in Patients with Newly Diagnosed Multiple Myeloma Treated with Novel Agents: Comparative Investigation with the Revised International Staging System
Abe, Yoshiaki
Narita, Kentaro
Kobayashi, Hiroki
Kitadate, Akihiro
Takeuchi, Masami
Matsue, Kosei
BLOOD, 2017, 130
[7] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Costa, Luciano J.
Chhabra, Saurabh
Godby, Kelly N.
Medvedova, Eva
Cornell, Robert F.
Hall, Aric C.
Silbermann, Rebecca W.
Innis-Shelton, Racquel
Dhakal, Binod
DeIdiaquez, Diego
Hardwick, Pamela
Biru, Yelak
Omel, James L.
Hari, Parameswaran
Callander, Natalie Scott
BLOOD, 2019, 134

← 1 →